Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Advances in chronic viral hepatitis.

Alex Yui Hui1, Joseph Jao-Yiu Sung

  • 1Department of Medicine and Therapeutics, Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong SAR, China.

Current Opinion in Infectious Diseases
|September 9, 2005
PubMed
Summary

Recent advances in treating chronic viral hepatitis B and C show promise. Pegylated interferon is a key treatment for hepatitis B, while combined pegylated interferon and ribavirin is standard for hepatitis C and HIV coinfection.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Tumor cells metabolically resist immune-checkpoint therapy by macrophage efferocytosis-mediated fatty acid recycling.

Cancer cell·2026
Same author

Colorectal cancer in metabolic dysfunction-associated steatotic liver disease: an international Delphi consensus statement.

Gut·2026
Same author

Risk-based screening programmes for cancer diagnosis: A systematic review with narrative synthesis.

Annals of the Academy of Medicine, Singapore·2025
Same author

A six-tiered framework for evaluating AI models from repeatability to replaceability.

Trends in biotechnology·2025
Same author

Multi-cohort analysis reveals colorectal cancer tumor location-associated fecal microbiota and their clinical impact.

Cell host & microbe·2025
Same author

Overcoming immunotherapy resistance in hepatocellular carcinoma by targeting myeloid IL-8/CXCR2 signaling.

Molecular therapy : the journal of the American Society of Gene Therapy·2025

Area of Science:

  • Hepatology
  • Virology
  • Immunology

Background:

  • Chronic liver disease from hepatitis B (HBV) and hepatitis C (HCV) can lead to cirrhosis and cancer.
  • Viral replication suppression improves prognosis.
  • Recent years have seen significant advancements in managing these viral hepatitis infections.

Purpose of the Study:

  • To review key publications from the past year on chronic viral hepatitis.
  • To enhance understanding of HBV and HCV management.
  • To highlight new treatment strategies and findings.

Main Methods:

  • Review of recent (past year) landmark studies and treatment trials.
  • Analysis of research on virus genotype effects.
  • Evaluation of new antiviral agents and treatment protocols.

Related Experiment Videos

Main Results:

  • Pegylated interferon shows efficacy in chronic hepatitis B, with potential as a first-line therapy.
  • Antiviral treatments benefit patients with advanced fibrosis or cirrhosis.
  • Pegylated interferon combined with ribavirin is effective for hepatitis C and HIV coinfection.

Conclusions:

  • Significant progress in treating chronic hepatitis B.
  • Pegylated interferon is emerging as a primary treatment for hepatitis B.
  • Combined pegylated interferon and ribavirin is the standard for hepatitis C/HIV coinfection.
  • Future research should focus on HBV/HIV coinfection and novel antiviral agents.